Abstract 4252: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers

Lauren Martires(Tango Therapeutics (United States)), Hilary E. Nicholson(Harvard University), Madhavi Bandi(Tango Therapeutics (United States)), Wenhai Zhang(Tango Therapeutics (United States)), William D. Mallender(Millennium Engineering and Integration (United States)), M. Tonini(Tango Therapeutics (United States)), Stephen Paik(Tango Therapeutics (United States)), Chengyin Min(Acetylon Pharmaceuticals (United States)), Jannik N. Andersen(Tango Therapeutics (United States)), Douglas A. Whittington(Amgen (United States)), Maria Dam Ferdinez(Tango Therapeutics (United States)), Alan Huang(Tango Therapeutics (United States)), EX Wu(Chinese University of Hong Kong), Patrick McCarren(Broad Institute), Katherine Lazarides(Tufts Medical Center), Shangtao Liu(Tango Therapeutics (United States)), Ashley H. Choi(Tango Therapeutics (United States)), Alice Tsai(Tango Therapeutics (United States)), Shan-Chuan Zhao(Takeda (Japan)), Frank J. Bruzzese(Millennium Engineering and Integration (United States)), Lauren Grove(Tango Therapeutics (United States)), Samuel R. Meier, Hannah Stowe(Massachusetts General Hospital), Teng Teng(Shanghai Jiao Tong University), Minjie Zhang(Xian Yang Central Hospital), Hongxiang Zhang(Huazhong Agricultural University), B.W. Shen(Io Therapeutics (United States)), Alvin Lu(Tango Therapeutics (United States)), Yi Yu(China Three Gorges Corporation (China)), Charlotte B. Pratt(Tango Therapeutics (United States))
Cancer Research
April 21, 2025
Cited by 0


Related Papers